Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.92 USD
Change Today -0.36 / -2.93%
Volume 174.6K
XNCR On Other Exchanges
As of 8:10 PM 10/12/15 All times are local (Market data is delayed by at least 15 minutes).

xencor inc (XNCR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $24.82
52 Week Low
10/13/14 - $9.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XENCOR INC (XNCR)

Related News

No related news articles were found.

xencor inc (XNCR) Related Businessweek News

No Related Businessweek News Found

xencor inc (XNCR) Details

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical trials for the treatment of B-cell cancers. It has a strategic collaboration with Amgen Inc. to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation; collaboration and license agreements with Novo Nordisk A/S and MorphoSys AG; collaboration and option agreement with Amgen Inc.; option and license agreement with Alexion Pharmaceuticals, Inc.; and a collaboration agreement with Boehringer Ingelheim International GmbH, as well as development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is headquartered in Monrovia, California.

37 Employees
Last Reported Date: 02/23/15
Founded in 1997

xencor inc (XNCR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $369.0K
Chief Business Officer
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $289.3K
Compensation as of Fiscal Year 2014.

xencor inc (XNCR) Key Developments

Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM

Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.

Xencor's Partner CSL Limited Initiates Phase 2 Clinical Trial of Biologic Candidate Using XmAb Cytotoxic Fc Domain

Xencor, Inc. announced that its partner CSL Limited has initiated, through its licensee Janssen Biotech Inc., a Phase 2 clinical trial for CSL362 (now called JNJ-56022473), which uses Xencor's XmAb Cytotoxic Fc Domain. Xencor will receive an undisclosed milestone payment for the initiation of Phase 2 testing. Under the terms of the agreement signed in February 2009, Xencor granted CSL Limited a non-exclusive license to Xencor Cytotoxic Fc Domains for use in CSL programs, including CSL362. Xencor is also eligible to receive additional milestone payments and royalties on sales. In 2013, CSL Limited licensed CSL362 to Janssen Biotech Inc.

Amgen, Xencor Enter into a Research and License Agreement to Develop Cancer Immunotherapy Treatments

Amgen and Xencor entered into a research and license agreement that could be worth as much as $1.7 billion to develop and commercialize therapeutics focused on cancer immunotherapy and inflammation. Under the partnership, Amgen will be in charge of preclinical and clinical development and commercialization, drawing on its background in protein therapeutics, while Xencor will contribute molecular engineering and bispecific molecules through its trademarked XmAb technology platform. The drug discovery will center on five Amgen-suggested antibody programs, and one specifically dedicated to multiple myeloma. Financially, Amgen will pay Xencor $45 million upfront and up to $1.7 billion for potential clinical, regulatory and sales milestones for six oncology programs, the companies said. Xencor could also receive royalties for developed medications and use of its CD38 bispecific T cell engager.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNCR:US $11.92 USD -0.36

XNCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XNCR.
View Industry Companies

Industry Analysis


Industry Average

Valuation XNCR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENCOR INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at